Media stories about Abbott Laboratories (NYSE:ABT) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Abbott Laboratories earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned news stories about the healthcare product maker an impact score of 46.7925784806752 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the news stories that may have effected Accern Sentiment’s analysis:

Several analysts have issued reports on the company. Citigroup Inc. assumed coverage on Abbott Laboratories in a research note on Thursday, August 17th. They issued a “neutral” rating and a $53.00 target price on the stock. Zacks Investment Research upgraded Abbott Laboratories from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a research note on Friday, September 22nd. Barclays PLC boosted their target price on Abbott Laboratories from $57.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, September 28th. J P Morgan Chase & Co assumed coverage on Abbott Laboratories in a research note on Friday, October 6th. They issued a “neutral” rating and a $60.00 target price on the stock. Finally, Jefferies Group LLC restated a “buy” rating and issued a $65.00 target price on shares of Abbott Laboratories in a research note on Thursday, October 19th. Seven equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $56.81.

Abbott Laboratories (ABT) traded down $0.15 during midday trading on Monday, hitting $55.41. The stock had a trading volume of 1,648,674 shares, compared to its average volume of 6,675,520. Abbott Laboratories has a 12 month low of $37.38 and a 12 month high of $56.69. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.26 and a current ratio of 2.69. The company has a market cap of $96,150.00, a price-to-earnings ratio of 23.05, a PEG ratio of 2.08 and a beta of 1.55.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.01. Abbott Laboratories had a return on equity of 13.98% and a net margin of 8.37%. The company had revenue of $6.83 billion during the quarter, compared to analyst estimates of $6.72 billion. During the same quarter in the previous year, the company posted $0.59 EPS. Abbott Laboratories’s revenue for the quarter was up 28.8% on a year-over-year basis. sell-side analysts anticipate that Abbott Laboratories will post 2.5 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th were paid a $0.265 dividend. This represents a $1.06 dividend on an annualized basis and a dividend yield of 1.91%. The ex-dividend date of this dividend was Thursday, October 12th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 87.60%.

In other news, insider Daniel Gesua Sive Salvadori sold 71,157 shares of the stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $55.00, for a total value of $3,913,635.00. Following the completion of the transaction, the insider now owns 144,955 shares of the company’s stock, valued at approximately $7,972,525. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jaime Contreras sold 52,700 shares of the stock in a transaction that occurred on Friday, September 22nd. The stock was sold at an average price of $51.97, for a total value of $2,738,819.00. Following the completion of the transaction, the insider now directly owns 58,739 shares of the company’s stock, valued at approximately $3,052,665.83. The disclosure for this sale can be found here. Insiders have sold a total of 282,920 shares of company stock valued at $15,389,766 in the last ninety days. 0.76% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Abbott Laboratories (ABT) Share Price” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.dailypolitical.com/2017/11/20/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-abbott-laboratories-abt-share-price.html.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Insider Buying and Selling by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.